Figures & data
Figure 1. Flow chart of patients with primary and recurrent GCTB
a Excluded were patients primarily treated with curettage without PMMA (n = 10), systemic treatment (n = 5), embolization (n = 1), or follow-up of less than 24 months (n = 10).
b Patients who were primarily treated for GCTB by curettage with adjuvants in a center not specialized in orthopedic oncology, and who were later referred with a first recurrence to our orthopedic oncology center for repeat curettage with adjuvants.
![Figure 1. Flow chart of patients with primary and recurrent GCTB a Excluded were patients primarily treated with curettage without PMMA (n = 10), systemic treatment (n = 5), embolization (n = 1), or follow-up of less than 24 months (n = 10). b Patients who were primarily treated for GCTB by curettage with adjuvants in a center not specialized in orthopedic oncology, and who were later referred with a first recurrence to our orthopedic oncology center for repeat curettage with adjuvants.](/cms/asset/fc00a30d-4b8e-4ec5-8ee4-ca1c2c16d80b/iort_a_711193_f0001_b.jpg)
Table 1. Patient demographics
Table 2. Recurrence-free survival for primary and recurrent GCTB
Figure 2. Kaplan-Meier estimated recurrence-free survival of primary GCTBs treated with curettage with PMMA and phenol (n = 75; green) or PMMA alone (n = 18; blue ) (p = 0.94).
![Figure 2. Kaplan-Meier estimated recurrence-free survival of primary GCTBs treated with curettage with PMMA and phenol (n = 75; green) or PMMA alone (n = 18; blue ) (p = 0.94).](/cms/asset/3504b641-f672-4642-9a6c-dcb2bb9d5e0d/iort_a_711193_f0002_b.jpg)
Figure 3. Kaplan-Meier estimated recurrence-free survival of recurrent GCTBs treated with curettage with PMMA and phenol (n = 21; green) or PMMA alone (n = 9; blue) (p = 0.99).
![Figure 3. Kaplan-Meier estimated recurrence-free survival of recurrent GCTBs treated with curettage with PMMA and phenol (n = 21; green) or PMMA alone (n = 9; blue) (p = 0.99).](/cms/asset/51eb5571-9ea9-4c71-87a9-70cb2e9c6a71/iort_a_711193_f0003_b.jpg)
Table 3. Potential individual risk factors for recurrence in GCTB
Table 4. Overview of recent studies on risk factors for recurrence and surgical management of primary GCTB